Yıl: 2021 Cilt: 17 Sayı: 3 Sayfa Aralığı: 183 - 189 Metin Dili: Türkçe İndeks Tarihi: 19-02-2022

Arctiin maddesinin lipopolisakkarit indüklü periodontal hastalık modeli üzerindeki antienflamatuvar etkinliğinin incelenmesi: Pilot çalışma

Öz:
Amaç: Arctiin maddesinin birçok dokuda enflamasyonu inhibe ettiği gösterilmiştir ancak bu etkilerin periodontal dokularda da olup olmadığı araştırılmamıştır. Bu çalışmanın amacı arctiin maddesinin periodontal hastalıklı rat gingival dokularında pro-enflamatuvar sitokin seviyelerinde bir azalmaya neden olup olmadığını incelemektir. Gereç ve Yöntem: Çalışma 30 adet erkek Sprague-Dawley sıçan ile yapıldı. Deneysel periodontal hastalık, kontrol grubu (n = 10) hariç, sıçanların birinci ve ikinci sol maksiller azı dişleri arasına lipopolisakkarit (LPS) enjekte edilerek oluşturuldu. Deney gruptaki sıçanlar rastgele iki gruba ayrıldı (Grup DP: Deneysel plasebo-Dimetil sülfoksit (DMSO); Grup DA: Deneysel Arctiin, herbiri n = 10). 21 gün boyunca günde bir kez ağızdan gavaj yapıldı. Daha sonra tüm hayvanlara ötenazi uygulandı, dişeti örnekleri alındı ve interleukin-1ß (IL-1 ß) ve tümör nekroz faktörü- a (TNF-a) ELISA ile analiz edildi. Bulgular: Kontrol grubu, deney grupları (Grup DP ve DA) ile karşılaştırıldığında diş eti dokusuna, IL-1ß ve TNF-a seviyeleri kontrol grubunda istatistiksel olarak anlamlı düzeyde az bulundu (P<0,001). DA grubu ise DP grubuna göre istatistiksel olarak daha düşük seviyelerde pro-enflamatuvar sitokin seviyeleri gösterdi (P<0,001). Sonuç: Arctiin maddesinin, LPS ile indüklenmiş periodontitisli sıçanların gingival dokularında proinflamatuar sitokin düzeylerini düşürdüğü gösterilmiştir.
Anahtar Kelime:

Anti-inflammatory effects of arctiin in a rat model of lipopolysaccaharideinduced periodontal disease: A pilot study

Öz:
Aim: Arctiin has been shown to inhibit inflammatory processes in various tissues, but its effects on periodontium have yet to be examined. Therefore, the aim of this study was to evaluate whether arctiin reduces pro-inflammatory cytokine levels in gingival tissues of rats with periodontal disease. Materials and Method: The study was conducted with 30 male Sprague-Dawley rats. Experimental periodontal disease was induced by injecting lipopolysaccharide (LPS) between the first and second left maxillary molar teeth of rats, except control group (n=10). Experimental rats were randomly divided into two groups (Group EP: Experimental placebo-Dimethyl sulphoxide (DMSO); Group EA: Experimental Arctiin, n=10 each). Oral gavage carried out once per day for 21 days. All animals were then euthanized, gingival samples were obtained, and interleukin-1ß (IL-1ß) and tumor necrosis factor-a (TNF-a) were analysed by ELISA. Results: Gingival tissue IL-1ß and TNF-a levels were significantly lower in the Control Group compared to both experimental groups (EP and EA) (P<0.001). EA group presented lower pro-inflammatory cytokine levels than those of non-arctiin treated placebo group (P<0.001). Conclusion: Arctiin was shown to reduce pro-inflammatory cytokine levels in gingival tissues of rats with LPS-induced periodontitis.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Armitage GC. Development of a classification system for periodontal diseases and conditions. Annals of Periodontol 1999;4:1-6.
  • 2. CHO MI, Garant PR. Development and general structure of the periodontium. Periodontol 2000. 2000;24:9- 27.
  • 3. Page R. Current understanding of the aetiology and progression of periodontal disease. Int Dent J 1986;36:153- 161.
  • 4. Socransky S, Haffajee A, Cugini M, Smith C, Kent Jr R. Microbial complexes in subgingival plaque. J Clin Periodontol 1998;25:134-144.
  • 5. Reddy MS, Geurs NC, Jeffcoat RL, Proskin H, Jeffcoat MK. Periodontal Disease Progression. J Periodontol 2000;71:1583-1590.
  • 6. Schenkein HA. Host responses in maintaining periodontal health and determining periodontal disease. Periodontol 2000 2006;40:77-93.
  • 7. Kantarci A, Hasturk H, Van Dyke TE. Host-mediated resolution of inflammation in periodontal diseases. Periodontol 2000 2006;40:144-163.
  • 8. Kirkwood KL, Cirelli JA, Rogers JE, Giannobile WV. Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 2007;43:294-315.
  • 9. Offenbacher S. Periodontal diseases: pathogenesis. Ann Periodontol 1996;1:821-878.
  • 10. Souza JACd, Junior CR, Garlet GP, Nogueira AVB, Cirelli JA. Modulation of host cell signaling pathways as a therapeutic approach in periodontal disease. Journal of Applied Oral Science 2012;20:128-138.
  • 11. Gemmell E, Marshall RI, Seymour GJ. Cytokines and prostaglandins in immune homeostasis and tissue destruction in periodontal disease. Periodontology 2000 1997;14:112-143.
  • 12. Lamster IB, Novak MJ. Host mediators in gingival crevicular fluid: implications for the pathogenesis of periodontal disease. Crit Rev Oral Biol Med 1992;3:31-60.
  • 13. Okada H, Murakami S. Cytokine expression in peri-odontal health and disease. Crit Rev Oral Biol Med 1998;9:248-266.
  • 14. Salvi G, Lang N. The effects of non-steroidal anti- inflammatory drugs (selective and non-selective) on the treatment of periodontal diseases. Curr Pharm Des 2005;11:1757-1769.
  • 15. Botelho M, Rao V, Carvalho C, Bezerra-Filho J, Fonseca S, et al. Lippia sidoides and Myracrodruon urundeuva gel prevents alveolar bone resorption in experimental periodontitis in rats. J Ethnopharmacol 2007;113:471- 478.
  • 16. Cao CF, Sun XP. Herbal medicine for periodontal diseases. Int Dent J 1998;48:316-321.
  • 17. Chan Y, Lai C-H, Yang H-W, Lin Y-Y, Chan C-H. The evaluation of Chinese herbal medicine effectiveness on periodontal pathogens. The Am J Chinese Med 2003;31:751-761.
  • 18. Sastravaha G, Gassmann G, Sangtherapitikul P, Grimm W-D. Adjunctive periodontal treatment with Centella asiatica and Punica granatum extracts in supportive periodontal therapy. J Int Acad Periodontol 2005;7:70- 79.
  • 19. Shannon J, Shannon J, Modelevsky S, Grippo AA. Bisphosphonates and osteonecrosis of the jaw. J Am Geriatr Soc 2011;59:2350-2355.
  • 20. Park SY, Hong SS, Han XH, Hwang JS, Lee D, et al. Lignans from Arctium lappa and their inhibition of LPS-induced nitric oxide production. Chem Pharm Bull (Tokyo). 2007;55:150-152.
  • 21. Chan Y-S, Cheng L-N, Wu J-H, Chan E, Kwan Y-W, et al. A review of the pharmacological effects of Arctium lappa (burdock). Inflammopharmacol 2011;19:245-254.
  • 22. Lin C-C, Lin J-M, Yang J-J, Chuang S-C, Ujiie T. Anti- inflammatory and radical scavenge effects of Arctium lappa. The Am J Chinese Med 1996;24:127-137.
  • 23. Guo M, Liang J, Wu S. On-line coupling of counter-current chromatography and macroporous resin chromatography for continuous isolation of arctiin from the fruit of Arctium lappa L. J Chromatogr A 2010;1217:5398-5406.
  • 24. Lee MH, Lee JM, Jun SH, Ha CG, Lee SH, et al. In-vitro and in-vivo anti-inflammatory action of the ethanol extract of Trachelospermi caulis. J Pharm Pharmacol 2007;59:123-130.
  • 25. Lee S, Shin S, Kim H, Han S, Kim K, et al. Anti-inflammatory function of arctiin by inhibiting COX-2 expression via NF-1B pathways. J Inflamm 2011;8:16.
  • 26. Liu H, Zhang Y, Sun Y, Wang X, Zhai Y, et al. Determination of the major constituents in fruit of Arctium lappa L. by matrix solid-phase dispersion extraction coupled with HPLC separation and fluorescence detection. J Chromatography B 2010;878:2707-2711.
  • 27. Liu S, Chen K, Schliemann W, Strack D. Isolation and identification of arctiin and arctigenin in leaves of burdock (Arctium lappa L.) by polyamide column chromatography in combination with HPLC-ESI [sol] MS. Phytochemical Analysis: Int J Plant Chem BiochemTech 2005;16:86-89.
  • 28. Matsuzaki Y, Koyama M, Hitomi T, Yokota T, Kawanaka M, et al. Arctiin induces cell growth inhibition through the down-regulation of cyclin D1 expression. Oncol Rep 2008;19:721-727.
  • 29. Wu J-G, Wu J-Z, Sun L-N, Han T, Du J, et al. Ameliorative effects of arctiin from Arctium lappa on experimental glomerulonephritis in rats. Phytomedicine 2009;16:1033- 1041.
  • 30. Kador PF, O'Meara JD, Blessing K, Marx DB, Reinhardt RA. Efficacy of structurally diverse aldose reductase inhibitors on experimental periodontitis in rats. J Periodontol 2011;82:926-933.
  • 31. Sakallıoğlu EE, Ayas B, Sakallıoğlu U, Açıkgöz G, Çağlayan F. Osmotic pressure and vasculature of gingiva in periodontal disease: an experimental study in rats. Arch Oral Biol 2006;51:505-511.
  • 32. Genco CA, Van Dyke T, Amar S. Animal models for Porphyromonas gingivalis-mediated periodontal disease. Trends Microbiol 1998;6:444-449.
  • 33. Paquette DW, Williams RC. Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases. Periodontol 2000 2000;24:239-252.
  • 34. Delima A, Oates T, Assuma R, Schwartz Z, Cochran D, et al. Soluble antagonists to interleukin-1 (IL-1) and tumor necrosis factor (TNF) inhibits loss of tissue attachment in experimental periodontitis. J Clin Periodontol 2001;28:233-240.
  • 35. Delima AJ, Karatzas S, Amar S, Graves DT. Inflammation and tissue loss caused by periodontal pathogens is reduced by interleukin-1 antagonists. J Infec Diseases 2002;186:511-516.
  • 36. Oates T, Graves D, Cochran DL. Clinical, radiographic and biochemical assessment of IL-1/TNF-a antagonist inhibition of bone loss in experimental periodontitis. J Clin Periodontol 2002;29:137-143.
  • 37. Fan H, De-Qiang D, Yu S, Ting-Guo K. Determination of Arctiin in rat plasma by HPLC method and its application to pharmacokinetic studies. J Med Plants Res 2011;5:549-557.
  • 38. de Molon RS, de Avila ED, Cirelli JA. Host responses induced by different animal models of periodontal disease: a literature review. J Invest Clin Dent 2013;4:211- 218.
  • 39. Rogers JE, Li F, Coatney DD, Rossa Jr C, Bronson P, et al. Actinobacillus actinomycetemcomitans lipopolysaccharide- mediated experimental bone loss model for aggressive periodontitis. J Periodontol 2007;78:550-558.
  • 40. de Aquino SG, Guimaraes MR, Stach-Machado DR, da Silva JAF, Spolidorio LC, et al. Differential regulation of MMP-13 expression in two models of experimentally induced periodontal disease in rats. Arch Oral Biol 2009;54:609-617.
  • 41. de Aquino SG, Leite FRM, Stach-Machado DR, da Silva JAF, Spolidorio LC, et al. Signaling pathways associated with the expression of inflammatory mediators activated during the course of two models of experimental periodontitis. Life Sci 2009;84:745-754.
  • 42. Genco RJ. Host responses in periodontal diseases: current concepts. J Periodontol 1992;63:338-355.
  • 43. Sugita N, Kimura A, Matsuki Y, Yamamoto T, Yoshie H, et al. Activation of transcription factors and IL-8 expression in neutrophils stimulated with lipopolysaccharide from Porphyromonas gingivalis. Inflam 1998;22:253-267.
  • 44. Yoshimura A, Hara Y, Kaneko T, Kato I. Secretion of IL-1, TNF-a, IL-8 and IL-1ra by human polymorphonuclear leukocytes in response to lipopolysaccharides from periodontopathic bacteria. J Periodon Res 1997;32:279-286.
APA AYDOĞDU A, SAKALLIOGLU E, Alaçam H (2021). Arctiin maddesinin lipopolisakkarit indüklü periodontal hastalık modeli üzerindeki antienflamatuvar etkinliğinin incelenmesi: Pilot çalışma. , 183 - 189.
Chicago AYDOĞDU AHMET,SAKALLIOGLU ELIF ESER,Alaçam Hasan Arctiin maddesinin lipopolisakkarit indüklü periodontal hastalık modeli üzerindeki antienflamatuvar etkinliğinin incelenmesi: Pilot çalışma. (2021): 183 - 189.
MLA AYDOĞDU AHMET,SAKALLIOGLU ELIF ESER,Alaçam Hasan Arctiin maddesinin lipopolisakkarit indüklü periodontal hastalık modeli üzerindeki antienflamatuvar etkinliğinin incelenmesi: Pilot çalışma. , 2021, ss.183 - 189.
AMA AYDOĞDU A,SAKALLIOGLU E,Alaçam H Arctiin maddesinin lipopolisakkarit indüklü periodontal hastalık modeli üzerindeki antienflamatuvar etkinliğinin incelenmesi: Pilot çalışma. . 2021; 183 - 189.
Vancouver AYDOĞDU A,SAKALLIOGLU E,Alaçam H Arctiin maddesinin lipopolisakkarit indüklü periodontal hastalık modeli üzerindeki antienflamatuvar etkinliğinin incelenmesi: Pilot çalışma. . 2021; 183 - 189.
IEEE AYDOĞDU A,SAKALLIOGLU E,Alaçam H "Arctiin maddesinin lipopolisakkarit indüklü periodontal hastalık modeli üzerindeki antienflamatuvar etkinliğinin incelenmesi: Pilot çalışma." , ss.183 - 189, 2021.
ISNAD AYDOĞDU, AHMET vd. "Arctiin maddesinin lipopolisakkarit indüklü periodontal hastalık modeli üzerindeki antienflamatuvar etkinliğinin incelenmesi: Pilot çalışma". (2021), 183-189.
APA AYDOĞDU A, SAKALLIOGLU E, Alaçam H (2021). Arctiin maddesinin lipopolisakkarit indüklü periodontal hastalık modeli üzerindeki antienflamatuvar etkinliğinin incelenmesi: Pilot çalışma. 7tepe Klinik, 17(3), 183 - 189.
Chicago AYDOĞDU AHMET,SAKALLIOGLU ELIF ESER,Alaçam Hasan Arctiin maddesinin lipopolisakkarit indüklü periodontal hastalık modeli üzerindeki antienflamatuvar etkinliğinin incelenmesi: Pilot çalışma. 7tepe Klinik 17, no.3 (2021): 183 - 189.
MLA AYDOĞDU AHMET,SAKALLIOGLU ELIF ESER,Alaçam Hasan Arctiin maddesinin lipopolisakkarit indüklü periodontal hastalık modeli üzerindeki antienflamatuvar etkinliğinin incelenmesi: Pilot çalışma. 7tepe Klinik, vol.17, no.3, 2021, ss.183 - 189.
AMA AYDOĞDU A,SAKALLIOGLU E,Alaçam H Arctiin maddesinin lipopolisakkarit indüklü periodontal hastalık modeli üzerindeki antienflamatuvar etkinliğinin incelenmesi: Pilot çalışma. 7tepe Klinik. 2021; 17(3): 183 - 189.
Vancouver AYDOĞDU A,SAKALLIOGLU E,Alaçam H Arctiin maddesinin lipopolisakkarit indüklü periodontal hastalık modeli üzerindeki antienflamatuvar etkinliğinin incelenmesi: Pilot çalışma. 7tepe Klinik. 2021; 17(3): 183 - 189.
IEEE AYDOĞDU A,SAKALLIOGLU E,Alaçam H "Arctiin maddesinin lipopolisakkarit indüklü periodontal hastalık modeli üzerindeki antienflamatuvar etkinliğinin incelenmesi: Pilot çalışma." 7tepe Klinik, 17, ss.183 - 189, 2021.
ISNAD AYDOĞDU, AHMET vd. "Arctiin maddesinin lipopolisakkarit indüklü periodontal hastalık modeli üzerindeki antienflamatuvar etkinliğinin incelenmesi: Pilot çalışma". 7tepe Klinik 17/3 (2021), 183-189.